Elotuzumab, a humanized CS1 antibody (Clone HuLuc63) that binds to the proximal C2 domain of CS1 is an effective anti-myeloma therapy when used in combination with lenalidomide and dexamethasone and without serious toxicity [10, 11] suggesting targeting CS1 with CAR-T will be effective and safe. This evidence concerns the gene SLAMF7 and plasma cell myeloma.